Our humble beginnings
Like most CROs, Databean’s management team started in academia then moved to industry before coming together in 2007 to found Databean. We were driven by the lack of comprehensive and affordable clinical trial solutions for medtech and biotech start-ups. Our primary mission is to foster the rapid growth of these companies so they can bring their technologies to market as soon as possible.
Founder and Managing Partner
Nuala co-founded Databean in 2007 after more than 20 years in the healthcare arena, 15 of which were in academic and industry-sponsored research. Nuala has extensive knowledge and training around key clinical, regulatory, and data management requirements essential for the successful execution of global clinical trials. With a degree in nursing and her ‘infectious enthusiasm’ for new technologies, Nuala can quickly assess the value of these new products and works hard to bring them to reality. When not working, Nuala manages a busy household of three boys. Her favorite charity is Kiva because everyone deserves a chance to realize their dreams.
Peter Terrizzi, MS
Founder and CTO
Peter Terrizzi is an expert in database architecture and development of web-based applications, creating robust solutions for complex technical problems. Peter possesses elite domain knowledge in e-Commerce, Financial Accounting, Insurance, Inventory Management, and Healthcare, where he led the life-cycle development and maintenance of mission-critical software applications, including TrialPoint™ e-clinical solutions. With a master’s in computer science, Peter runs the tech and security teams, ensuring TrialPoint’s compliance with global standards. When not busy with those tasks, he designs new modular applications based on TrialPoint’s business objectives and Sponsor needs. On a personal note, Peter has no other life as we don’t let him out of the basement.
Founder and Application Developer
Utilizing an extensive foundation in both clinical research and data management, Hal co-founded Databean in 2007, seeking an optimal solution in the ever-changing healthcare IT industry. Hal’s experience in interactive design and development of web-based applications, as well as his expertise in data integrity and security, resulted in TrialPoint™, a comprehensive research management system that serves the data collection and management needs of Databean’s clients. More recently, Hal is exploring the integration of mHealth applications to help transform the clinical trial process. When not working, Hal enjoys coaching school sports and his favorite charity is code.org…..go figure!
Michael Parides, Ph.D
Michael Parides is the Director of Biostatistics at the Icahn School of Medicine at Mount Sinai, NY, and oversees trial design and data management for Databean. Michael earned his Ph.D in Biostatistics from Columbia University and has 25+ years of experience in the design of complex clinical studies. He has been the principal statistician on numerous landmark trials in stroke and cardiovascular disease and employs a pragmatic approach to trial design for novel technologies, believing strongly in Bayesian techniques. Michael has developed excellent working relationships with the NIH and the FDA, serving as a DSMB committee chair and panel advisor. Despite his solid “pocket protector” status, Michael has a fantastic sense of humor and a passion for new technologies.
Deborah Arthur, MA
Deborah Arthur is Databean’s key regulatory strategist. She is instrumental in providing global management of regulatory and quality requirements within clinical trials. Having served as Vice President of Regulatory and Quality for several medical device companies, including Cochlear Americas, MetaCure and Symphonix Devices, Deborah is an expert at crafting regulatory pathways for novel devices and her no-nonsense approach is much appreciated by our clients and the regulatory authorities around the world. When not keeping us grounded at Databean, Deborah loves to spend time with her grandchildren and grow beautiful flowers in her garden.
End Stage Renal Disease
Drugs and biologics
Ischemic Heart Disease
Class III medical devices